| 2026 |
| 06/05 | （IR情報）15:30 (訂正・数値データ訂正)修正後発事象による引当金の計上および「2026年3月期決算短信〔IFRS〕(連結)」の修正について |
| 06/05 | 4,933 | 4,977 | 4,909 | 4,926 | +1.57% | 4,448,200 | 7兆8382億 | -3.94% |
| 06/04 | 4,800 | 4,880 | 4,766 | 4,850 | +2.15% | 4,360,600 | 7兆7173億 | -5.64% |
| 06/03 | 4,800 | 4,809 | 4,710 | 4,748 | -2.1% | 5,041,600 | 7兆5550億 | -7.97% |
| 06/02 | 4,837 | 4,905 | 4,784 | 4,850 | -0.64% | 5,212,500 | 7兆7173億 | -6.42% |
| 06/01 | （IR情報）16:00 新株式発行に係る発行登録の取下げ及び新たな発行登録に関するお知らせ |
| 06/01 | 5,045 | 5,059 | 4,861 | 4,881 | -4.63% | 6,637,600 | 7兆7666億 | -6.15% |
| 06/01 | （空売り報告）Barclays Bank PLC 17,501,464株（1.09%）-0.03% |
| 05/29 | 5,079 | 5,146 | 5,074 | 5,118 | -0.04% | 7,712,000 | 8兆1437億 | -2.07% |
| 05/28 | 5,128 | 5,182 | 5,113 | 5,120 | -0.16% | 3,797,500 | 8兆1469億 | -2.36% |
| 05/27 | 5,090 | 5,130 | 5,056 | 5,128 | +1.34% | 3,687,000 | 8兆1596億 | -2.57% |
| 05/26 | 5,070 | 5,070 | 5,027 | 5,060 | -0.86% | 3,534,300 | 8兆514億 | -4.22% |
| 05/25 | 5,141 | 5,166 | 5,077 | 5,104 | -0.1% | 3,811,800 | 8兆1215億 | -3.83% |
| 05/22 | 5,190 | 5,206 | 5,109 | 5,109 | -1.37% | 3,742,400 | 8兆1294億 | -4.09% |
| 05/21 | 5,300 | 5,320 | 5,180 | 5,180 | -1.43% | 3,251,600 | 8兆2424億 | -3.14% |
| 05/20 | 5,323 | 5,362 | 5,187 | 5,255 | 0% | 4,328,700 | 8兆3617億 | -2.14% |
| 05/19 | （IR情報）10:20 AMITIZA(ルビプロストン)に係る米国の反トラスト訴訟における陪審評決および関連する2026年3月期(2025年度)決算値の修正について |
| 05/19 | 5,325 | 5,352 | 5,244 | 5,255 | +0.11% | 4,414,600 | 8兆3617億 | -2.56% |
| 05/18 | 5,291 | 5,309 | 5,221 | 5,249 | -0.53% | 3,372,900 | 8兆3522億 | -3.05% |
| 05/15 | 5,256 | 5,327 | 5,252 | 5,277 | +0.4% | 5,258,600 | 8兆3967億 | -2.92% |
| 05/14 | 5,124 | 5,288 | 5,039 | 5,256 | +1.23% | 5,453,200 | 8兆3633億 | -3.65% |
| 05/13 | （IR情報）16:00 当社取締役に対する株式報酬制度および国内の当社幹部に対する株式付与制度の2026年における継続について |
| 05/13 | （IR情報）15:30 2026年3月期決算短信〔IFRS〕(連結) |
| 05/13 | 5,193 | 5,234 | 5,174 | 5,192 | +0.46% | 3,887,700 | 8兆2615億 | -5.2% |
| 05/12 | 5,167 | 5,196 | 5,138 | 5,168 | +0.12% | 3,103,900 | 8兆2233億 | -6.12% |
| 05/11 | 5,207 | 5,222 | 5,151 | 5,162 | -0.98% | 4,684,400 | 8兆2137億 | -6.72% |
| 05/08 | 5,339 | 5,339 | 5,205 | 5,213 | -1.83% | 5,448,900 | 8兆2949億 | -6.14% |
| 05/07 | 5,206 | 5,338 | 5,195 | 5,310 | +1.36% | 6,380,200 | 8兆4492億 | -4.74% |
| 05/01 | 5,260 | 5,260 | 5,191 | 5,239 | -0.59% | 2,628,900 | 8兆3363億 | -6.36% |
| 04/30 | 5,214 | 5,270 | 5,170 | 5,270 | -0.36% | 5,930,400 | 8兆3856億 | -6.18% |
| 04/28 | 5,292 | 5,295 | 5,224 | 5,289 | +1.36% | 3,363,300 | 8兆4158億 | -6.21% |
| 04/27 | 5,235 | 5,269 | 5,187 | 5,218 | -2.19% | 3,749,900 | 8兆3029億 | -7.71% |
| 04/24 | 5,352 | 5,378 | 5,306 | 5,335 | +0.08% | 2,389,900 | 8兆4890億 | -5.89% |
| 04/23 | 5,318 | 5,336 | 5,258 | 5,331 | +0.24% | 3,932,200 | 8兆4827億 | -6.24% |
| 04/22 | 5,485 | 5,494 | 5,316 | 5,318 | -3.1% | 4,930,100 | 8兆4620億 | -6.82% |
| 04/21 | 5,520 | 5,555 | 5,457 | 5,488 | -1.56% | 3,375,600 | 8兆7325億 | -4.17% |
| 04/20 | 5,622 | 5,626 | 5,545 | 5,575 | -0.2% | 3,105,300 | 8兆8709億 | -2.82% |
| 04/17 | 5,602 | 5,660 | 5,585 | 5,586 | -1.06% | 5,111,600 | 8兆8884億 | -2.7% |
| 04/16 | 5,676 | 5,716 | 5,639 | 5,646 | -0.14% | 3,812,900 | 8兆9839億 | -1.72% |
| 04/15 | 5,612 | 5,667 | 5,598 | 5,654 | +0.89% | 3,779,900 | 8兆9966億 | -1.65% |
| 04/14 | 5,669 | 5,685 | 5,582 | 5,604 | -0.57% | 3,179,400 | 8兆9171億 | -2.56% |
| 04/13 | 5,736 | 5,757 | 5,630 | 5,636 | -1.67% | 4,180,100 | 8兆9680億 | -2.02% |
| 04/10 | 5,750 | 5,774 | 5,696 | 5,732 | -1.53% | 4,293,400 | 9兆1207億 | -0.38% |
| 04/09 | 5,900 | 5,936 | 5,801 | 5,821 | +0.55% | 5,222,200 | 9兆2624億 | +1.23% |
| 04/08 | 5,914 | 5,920 | 5,763 | 5,789 | -0.16% | 5,197,100 | 9兆2114億 | +0.84% |
| 04/07 | 5,780 | 5,815 | 5,745 | 5,798 | +0.76% | 3,898,700 | 9兆2258億 | +1.03% |
| 04/06 | 5,809 | 5,834 | 5,754 | 5,754 | -0.83% | 2,326,500 | 9兆1557億 | +0.26% |
| 04/03 | 5,850 | 5,888 | 5,802 | 5,802 | -1.49% | 2,269,900 | 9兆2321億 | +1.06% |
| 04/02 | 6,000 | 6,033 | 5,885 | 5,890 | +0.03% | 4,584,000 | 9兆3721億 | +2.65% |
| 04/01 | 5,860 | 5,888 | 5,784 | 5,888 | +3.95% | 6,100,500 | 9兆3690億 | +2.67% |
| 03/31 | 5,727 | 5,769 | 5,645 | 5,664 | -0.86% | 5,766,200 | 9兆125億 | -1.19% |
| 03/30 | 5,521 | 5,721 | 5,515 | 5,713 | -2.17% | 6,439,900 | 9兆905億 | -0.42% |
| 03/30 | （IR情報）8:45 1日1回投与の利便性を備えた経口薬であるザソシチニブによる、迅速かつ持続的な皮膚症状の改善効果および乾癬治療を変革する可能性を示唆した臨床試験結果の発表 |
| 03/27 | 5,789 | 5,855 | 5,758 | 5,840 | +0.88% | 5,940,800 | 9兆2926億 | +1.72% |
| 03/26 | （IR情報）15:30 第150回定時株主総会に提案する取締役候補者および代表取締役の異動について |
| 03/26 | 5,813 | 5,816 | 5,738 | 5,789 | -0.53% | 3,651,500 | 9兆2114億 | +0.85% |
| 03/25 | （IR情報）17:30 競争力強化と将来の成長加速に向けた変革の次なるステップについて |
| 03/25 | 5,800 | 5,825 | 5,769 | 5,820 | +2.77% | 4,521,900 | 9兆2608億 | +1.55% |
| 03/24 | 5,645 | 5,674 | 5,623 | 5,663 | +1.54% | 3,192,300 | 9兆109億 | -0.98% |
| 03/23 | 5,642 | 5,680 | 5,553 | 5,577 | -3.31% | 5,922,600 | 8兆8734億 | -2.45% |
| 03/19 | 5,752 | 5,813 | 5,750 | 5,768 | -1.74% | 7,029,100 | 9兆1773億 | +0.86% |
| 03/18 | 5,797 | 5,877 | 5,791 | 5,870 | +0.86% | 3,873,700 | 9兆3396億 | +2.78% |
| 03/17 | 5,810 | 5,864 | 5,785 | 5,820 | +1.45% | 3,854,600 | 9兆2600億 | +2.16% |
| 03/17 | （空売り報告）Barclays Bank PLC 17,859,884株（1.12%）+0.12% |
| 03/16 | 5,671 | 5,760 | 5,633 | 5,737 | +1.13% | 5,565,800 | 9兆1280億 | +0.93% |
| 03/13 | 5,621 | 5,711 | 5,621 | 5,673 | +0.14% | 4,109,300 | 9兆262億 | -0.11% |
| 03/13 | （空売り報告）Barclays Bank PLC 15,999,857株（1%）+0.03% |
| 03/12 | 5,700 | 5,714 | 5,636 | 5,665 | -1.55% | 4,013,600 | 9兆134億 | -0.11% |
| 03/11 | 5,723 | 5,801 | 5,710 | 5,754 | +0.65% | 3,073,900 | 9兆1550億 | +1.64% |
| 03/10 | 5,717 | 5,721 | 5,661 | 5,717 | +1.78% | 4,424,500 | 9兆962億 | +1.28% |
| 03/09 | 5,517 | 5,648 | 5,509 | 5,617 | -1.23% | 5,182,700 | 8兆9371億 | -0.16% |
| 03/06 | 5,560 | 5,688 | 5,555 | 5,687 | +0.99% | 4,179,700 | 9兆484億 | +1.43% |
| 03/05 | 5,708 | 5,727 | 5,616 | 5,631 | +0.41% | 4,650,300 | 8兆9593億 | +0.86% |
| 03/04 | 5,608 | 5,639 | 5,562 | 5,608 | -2.08% | 5,848,200 | 8兆9227億 | +0.81% |
| 03/03 | 5,744 | 5,790 | 5,681 | 5,727 | -1.16% | 4,834,800 | 9兆1121億 | +3.34% |
| 03/02 | （IR情報）16:00 真性多血症に対するファースト・イン・クラスの治療薬となる可能性を有するrusfertideの米国FDAによる新薬承認申請受理および優先審査指定 |
| 03/02 | 5,765 | 5,806 | 5,715 | 5,794 | -0.43% | 4,193,100 | 9兆2187億 | +5% |
| 02/27 | 5,725 | 5,832 | 5,716 | 5,819 | +1.54% | 6,683,400 | 9兆2585億 | +6.05% |
| 02/26 | 5,769 | 5,800 | 5,731 | 5,731 | -1.22% | 5,181,000 | 9兆1184億 | +5.1% |
| 02/25 | 5,844 | 5,848 | 5,736 | 5,802 | -0.28% | 4,863,700 | 9兆2314億 | +6.91% |
| 02/24 | 5,839 | 5,840 | 5,705 | 5,818 | +0.48% | 4,169,500 | 9兆2569億 | +7.76% |
| 02/20 | 5,800 | 5,806 | 5,755 | 5,790 | -0.43% | 4,349,100 | 9兆2118億 | +7.84% |
| 02/19 | 5,730 | 5,830 | 5,694 | 5,815 | +0.1% | 5,527,000 | 9兆2515億 | +8.81% |
| 02/18 | 5,611 | 5,809 | 5,607 | 5,809 | +4.53% | 7,302,600 | 9兆2420億 | +9.23% |
| 02/17 | 5,555 | 5,582 | 5,524 | 5,557 | +0.4% | 2,877,200 | 8兆8411億 | +5.13% |
| 02/16 | 5,640 | 5,642 | 5,530 | 5,535 | -1.41% | 3,806,800 | 8兆8061億 | +5.09% |
| 02/13 | 5,650 | 5,650 | 5,574 | 5,614 | +0.09% | 5,177,800 | 8兆9318億 | +6.95% |
| 02/12 | 5,602 | 5,616 | 5,563 | 5,609 | +0.5% | 4,501,600 | 8兆9238億 | +7.39% |
| 02/10 | （IR情報）17:00 米国FDAによるナルコレプシータイプ1に対するファースト・イン・クラスの治療となる可能性を有するoveporexton(TAK-861)の新薬承認申請受理および優先審査指定 |
| 02/10 | 5,550 | 5,613 | 5,530 | 5,581 | +1.4% | 5,033,900 | 8兆8793億 | +7.43% |
| 02/09 | 5,640 | 5,640 | 5,491 | 5,504 | -0.24% | 5,755,300 | 8兆7567億 | +6.5% |
| 02/06 | 5,531 | 5,548 | 5,465 | 5,517 | -1.34% | 4,868,100 | 8兆7774億 | +7.29% |
| 02/05 | 5,515 | 5,616 | 5,441 | 5,592 | +1.9% | 6,752,600 | 8兆8968億 | +9.28% |
| 02/04 | 5,467 | 5,494 | 5,437 | 5,488 | +1.27% | 4,891,900 | 8兆7313億 | +7.86% |
| 02/03 | 5,399 | 5,467 | 5,372 | 5,419 | +1.44% | 5,962,100 | 8兆6215億 | +7.03% |
| 02/02 | 5,375 | 5,401 | 5,315 | 5,342 | +1.91% | 6,465,400 | 8兆4990億 | +5.97% |
| 01/30 | 5,226 | 5,328 | 5,213 | 5,242 | +1.73% | 8,948,500 | 8兆3399億 | +4.42% |
| 01/29 | （IR情報）15:30 2026年3月期第3四半期決算短信〔IFRS〕(連結) |
| 01/29 | 5,112 | 5,154 | 5,085 | 5,153 | +1.4% | 6,221,200 | 8兆1983億 | +3.1% |
| 01/28 | 5,103 | 5,125 | 5,059 | 5,082 | -0.94% | 4,706,100 | 8兆854億 | +2.13% |
| 01/27 | 5,090 | 5,145 | 5,059 | 5,130 | +0.81% | 4,939,200 | 8兆1617億 | +3.59% |
| 01/26 | 5,050 | 5,118 | 5,046 | 5,089 | -0.53% | 4,177,700 | 8兆965億 | +3.31% |
| 01/23 | 5,078 | 5,124 | 5,034 | 5,116 | +1.77% | 4,631,200 | 8兆1394億 | +4.34% |
| 01/22 | 5,053 | 5,064 | 5,002 | 5,027 | +1.07% | 5,853,000 | 7兆9978億 | +3.05% |
| 01/21 | 5,015 | 5,062 | 4,956 | 4,974 | -1.74% | 6,369,600 | 7兆9135億 | +2.45% |
| 01/20 | （IR情報）16:45 (訂正)尋常性乾癬を対象としたザソシチニブ1日1回経口投与で皮膚病変の改善をもたらし治療の新時代を切り開く可能性を示した画期的な第3相臨床試験データ |
| 01/20 | 5,086 | 5,100 | 5,030 | 5,062 | -0.86% | 5,335,500 | 8兆535億 | +4.69% |
| 01/19 | 5,070 | 5,106 | 5,048 | 5,106 | +0.65% | 3,666,200 | 8兆1235億 | +6.11% |
| 01/16 | 5,101 | 5,122 | 5,034 | 5,073 | -1.99% | 4,985,200 | 8兆710億 | +5.97% |
| 01/15 | 5,215 | 5,230 | 5,152 | 5,176 | +0.5% | 5,400,000 | 8兆2349億 | +8.67% |
| 01/14 | 5,070 | 5,196 | 5,068 | 5,150 | +2.59% | 7,101,100 | 8兆1935億 | +8.83% |
| 01/13 | 5,129 | 5,153 | 5,020 | 5,020 | -1.18% | 7,292,300 | 7兆9867億 | +6.7% |
| 01/09 | 5,065 | 5,098 | 5,019 | 5,080 | -0.14% | 5,141,400 | 8兆822億 | +8.5% |
| 01/08 | 4,999 | 5,089 | 4,987 | 5,087 | +2.73% | 6,317,000 | 8兆933億 | +9.21% |
| 01/07 | 4,913 | 4,975 | 4,883 | 4,952 | +0.79% | 5,151,500 | 7兆8785億 | +6.84% |
10年以上蓄積したファイナンスデータとAIを掛け合わせて、投資の意思決定を加速させるポジションです。
